Vaccine pioneer admits adding cancer-causing virus to Vaccine

Vaccine pioneer admits adding cancer-causing virus to Vaccine
In this interview Dr. Maurice Hilleman reveals some astounding revelations. He admits that Merck drug company vaccines (Polio) had been deliberately contaminated with SV40, a cancer-causing monkey virus from 1953 – 63.
For years, researchers suggested that millions of vials of polio vaccine, contaminated with SV40, infected individuals which caused human tumors, and by 1999, molecular evidence of SV40 infections were showing up in children born after 1982. Some experts now suggest the virus may have remained in the polio vaccine until as late as 1999.
In 2002, the journal Lancet published compelling evidence that contaminated polio vaccine was responsible for up to half of the 55,000 non-Hodgkin’s lymphoma cases that were occurring each year. And there is the likelihood that there was an importing and spreading of the AIDS virus in the same manner, as revealed in the video.
At first no one could fathom how the virus had been transmitted into the human population, but this shocking video proves that it was deliberately added to the vaccine by Dr. Maurice Hilleman, which was “good science” at that time.
Just Who is Dr. Maurice Hilleman?
Now, for those of you who may think Dr. Hilleman was just another crackpot (he passed away in 2005), think again. He was, and still is, the leading vaccine pioneer in the history of vaccines. He developed more than three dozen vaccines—more than any other scientist in history—and was the developer of Merck’s vaccine program.
He was a member of the U.S. National Academy of Science, the Institute of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society, and received a special lifetime achievement award from the World Health Organization.
When he was chief of the Department of Respiratory Diseases with what’s now the Walter Reed Army Institute of Research, he discovered the genetic changes that occur when the influenza virus mutates, known as shift and drift. He was also one of the early vaccine pioneers to warn about the possibility that simian viruses might contaminate vaccines.So Dr. Hilleman knew what he was talking about. And in his own words, “vaccines have to be considered the bargain basement technology for the 20th Century.”

CDC admits 98 million Americans were given cancer virus via the polio shot
The CDC has admitted that between 1955–1963 over 98 million Americans received one or more doses of a polio shot which was contaminated with a cancer-causing virus called Simian vacuolating virus 40 (SV40).  The CDC quickly took down the page, along with Google, but the site was luckily cached and saved to symbolize this grand admission.

Historical Vaccine Safety Concerns
Simian Virus 40(SV40) – 1955-1963
Some of the polio vaccine administered from 1955 to 1963 was contaminated with a virus called simian virus 40 (SV40). The virus came from the monkey kidney cells used to produce the vaccines.  Once the contamination was discovered in the Salk inactivated polio vaccine in use at that time, the U.S. government established requirements for vaccine testing to verify that all new batches of the polio vaccine were free of SV40. Because of research done with SV40 in animal models, there was some concern that the virus could cause cancer. However, evidence suggests that SV40 has not caused cancer in humans.

Volume 3, Number 2—June 1997
Simian Virus 40 (SV40), a Possible Human Polyomavirus (Workshop Held at NIH)
During the past 4 years, polymerase chain reaction (PCR) assays have detected DNA sequences related to SV40 (an oncogenic simian polyomavirus) in a variety of human tissues, especially choroid plexus tumors, ependymomas, mesotheliomas, and osteosarcomas (1-7). These findings were supported by the isolation of infectious SV40 from a choroid plexus tumor (8).
Although another paper reported the failure to detect SV40 DNA in mesotheliomas (9), these studies have reawakened interest in inadvertent human exposure to SV40 in the late 1950s and early 1960s when polio and adenovirus vaccines prepared in rhesus monkey cells containing SV40 were used (10,11). In response to the implications of detecting SV40 DNA in human tumors, the Food and Drug Administration, National Institutes of Health, National Vaccine Program Office, and Centers for Disease Control and Prevention sponsored a workshop on SV40 on January 27-28, 1997 at the National Institutes of Health to examine the possibility that SV40 is an infectious agent in humans.

The following statement is an introduction for a more detailed packet on SV-40 and animal viruses in the production of vaccines.

Statement by Barbara Loe Fisher, Co-Founder & President
National Vaccine Information Center
Workshop on Simian Virus-40 (SV-40): A Possible Human Polyomavirus
January 27-28, 1997
Bethesda, Maryland
The National Vaccine Information Center (NVIC), which was founded in 1982 and represents health care consumers and health care professionals concerned about vaccine safety, became actively involved in 1994 in researching reports of contamination of childhood vaccines with animal viruses and the possibility that inter-species transfer of animal viruses into humans via vaccines has had a negative impact on public health. Our concern was that government health agencies and industry had not adequately addressed many of the most important questions that remained unanswered about the contamination of polio vaccines with simian (monkey) viruses.

NIH Scientists Identify Potent Antibody that Neutralizes Nearly All HIV Strains

NIH Scientists Identify Potent Antibody that Neutralizes Nearly All HIV Strains
Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class. The remarkable breadth and potency of this antibody, named N6, make it an attractive candidate for further development to potentially treat or prevent HIV infection, say the researchers.
The scientists, led by Mark Connors, M.D., of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), also tracked the evolution of N6 over time to understand how it developed the ability to potently neutralize nearly all HIV strains. This information will help inform the design of vaccines to elicit such broadly neutralizing antibodies.
Identifying broadly neutralizing antibodies against HIV has been difficult because the virus rapidly changes its surface proteins to evade recognition by the immune system. In 2010, scientists at NIAID’s Vaccine Research Center (VRC) discovered an antibody called VRC01 that can stop up to 90 percent of HIV strains from infecting human cells. Like VRC01, N6 blocks infection by binding to a part of the HIV envelope called the CD4 binding site, preventing the virus from attaching itself to immune cells.
Findings from the current study showed that N6 evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.
The new findings suggest that N6 could pose advantages over VRC01, which currently is being assessed as intravenous infusions in clinical trials to see if it can safely prevent HIV infection in humans. Due to its potency, N6 may offer stronger and more durable prevention and treatment benefits, and researchers may be able to administer it subcutaneously (into the fat under the skin) rather than intravenously. In addition, its ability to neutralize nearly all HIV strains would be advantageous for both prevention and treatment strategies.